Cancer Genetics is a study of heritable gene variants that cause or confer altered risk of tumor or hematological malignancy. Genetic changes that promote cancer can be passed on from generation to generation if the changes are present in constitutional DNA. Cancer causing genetic changes can also be acquired during one’s lifetime, as the result of random errors of cell divisions or exposure to carcinogenic chemicals and radiations that damage DNA. Cancer genetic testing reveals a genetic predisposition to specific genetic variants that are often inherited from a parent.
360 Laboratories’ Pharmacogenetic Testing provides insight into a patient’s genetic propensity to experience a drug-to-drug interaction or to be non-responsive with certain medication classes. This information is invaluable to clinicians whether they are initiating therapy or evaluating a patient’s progress. We evaluate 49 separate genes and over 120 variants to create an easy to understand report on 15 drug classes and 182 pharmacologic agents. This provides clinicians with one of the most robust reports in the industry and will help guide the clinician’s choices in pharmacotherapy.
Currently 360 Laboratories offers Pharmacogenetic Testing Panels for the following medication classes:
Genetic Carrier Screening is a medical test to find out if you or your partner carry a genetic mutation that could lead to serious health consequences if inherited by your baby. The inherited disorders that we test for include; cystic fibrosis, sickle cell disease, beta thalassemia, Tay-Sachs disease and others (see full list below). While these diseases are somewhat rare, the average risk of having a baby born with one of these diseases is higher than the average risk of having a baby born with Down syndrome or a neural tube defect.
All of these disorders are recessive, which means that for a baby to be born with the disorder, both parents would have to be carriers. Carriers have inherited a normal copy of the gene from one parent and a defective copy of the gene from the other parent. So carriers usually do not exhibit symptoms of the disorder. When two carriers of the same disorder (such as cystic fibrosis or sickle cell disease) have a baby, there exists a twenty-five percent chance that the baby will have inherited two defective genes, and thereby be affected with the disorder.
Genetic Carrier Screening is performed either pre-conception or early in the first trimester of pregnancy on the mother and, if the mother is determined to be a carrier of a hereditary disorder, the father as well. This allows time for you to discuss with your health care provider or a genetic counselor if further diagnostic testing such as CVS (Chorionic villus sampling) and/or amniocentesis should be accomplished in order to determine the health status of your baby. Early screening may have many advantages. For some diseases, knowing your baby is affected before birth makes it more likely that your baby can be helped by early treatment. It allows you to line up the right medical specialists, who can be on hand to start treating your baby soon after delivery.
At 360 Laboratories, we believe that knowing is caring. That’s why our Genetic Carrier Screening panels are designed to tell you whether or not you, or your partner, are carriers for any of the hereditary disorders.
Our Genetic Carrier Screening panels are designed to tell you whether or not you, or your partner, are carriers for any of the following hereditary disorders:
ACOG / ACMG 13 with CF Panel
Niemann Pick Disease (Type A & B)
Spinal Muscular Atrophy
Tay – Sachs disease
Sickle Cell Disease
Duchenne/Becker Muscular Dystrophy